Xeltis Closes 45 Million in Oversubscribed Series C Financing to Advance Aortic and Pulmonary Valve Programs
The largest investment round for a private medical device company in Europe in 2017
EINDHOVEN, The Netherlands and ZURICH, November 15, 2017 -- (Healthcare Sales & Marketing Network) -- Xeltis, a clinical-stage medical device company pioneering a resto... Devices, Cardioloy, Venture Capital Xeltis , Endogenous Tissue Restoration, heart valve therapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Heart | Heart Valve Disease | Heart Valves | Marketing | Medical Devices | Netherlands Health | Venture Capital